Literature DB >> 20681930

Testosterone is not associated with mortality in older African-American males.

Lenise A Cummings-Vaughn1, Theodore K Malmstrom, John E Morley, Douglas K Miller.   

Abstract

INTRODUCTION. Although testosterone and its association with disease progression and mortality is a widely studied topic, no studies have evaluated mortality risks related to testosterone levels in an older African-American population. The mechanisms for known racial differences in mortality risk for certain cancers and cardiovascular risk factors are largely unknown. Elucidating a mortality risk associated with testosterone levels may give insight into the elevated risk for certain diseases in African-Americans. METHODS AND RESULTS. Study data were derived from a cohort 622 African-Americans (age 80.05  ±  6.4, range 68-102) from Saint Louis, Missouri that includes 190 males (age 79.38  ±  6.2, range 70-102). The eligible sample for this report includes 56 of the 190 males (age 78.89  ±  6.9, range 70-102) who donated blood at baseline in 1992-1994 and subsequently tested for total testosterone and bioavailable testosterone. Covariates for adjusted analyses were lower body functional limitations, physician visits and comorbidities, also collected at baseline. Males' mean bioavailable testosterone levels (ng/dl) were 33.33  ±  24.4 (n above 70 ng/dl = 5) and mean total testosterone levels (ng/dl) were 246.63  ±  118.7 (n above 300 ng/dl = 20). Vital status was determined through 2002; 41 males (73%) were deceased and 15 were alive. Mortality did not differ among males with testosterone levels <300 versus 300+ (p = 0.42) or with bioavailable testosterone levels <70 versus > 70 (p  =  0.34). Total testosterone levels did not predict mortality when adjusted for age (Adjusted Hazard Ratio [AHR] = 0.998; 95% confidence interval [CI] 0.995-1.001; p = 0.28) or adjusted for age and other covariates (AHR  =  0.099; 95% CI 0.996, 1.002; p  =  0.35). Bioavailable testosterone levels did not predict mortality when adjusted for age (AHR  =  0.992; 95% CI .977-1.007; p  =  0.30) or when adjusted for age and other covariates (AHR 0.991; 95% CI .976-1.006; p  =  0.261). CONCLUSION. In older African-American males, total and bioavailable testosterone levels, with and without adjustment for covariates, are not independently associated with mortality risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20681930      PMCID: PMC4519078          DOI: 10.3109/13685538.2010.502269

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  20 in total

1.  Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study.

Authors:  Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Circulation       Date:  2007-11-26       Impact factor: 29.690

2.  Mortality risk in older inner-city African Americans.

Authors:  Theodore K Malmstrom; Elena M Andresen; Fredric D Wolinsky; J Philip Miller; Kathryn Stamps; Douglas K Miller
Journal:  J Am Geriatr Soc       Date:  2007-07       Impact factor: 5.562

3.  Serum androgen levels in black, Hispanic, and white men.

Authors:  Heather J Litman; Shalender Bhasin; Carol L Link; Andre B Araujo; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

4.  Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study.

Authors:  George Davey Smith; Yoav Ben-Shlomo; Andrew Beswick; John Yarnell; Stafford Lightman; Peter Elwood
Journal:  Circulation       Date:  2005-07-11       Impact factor: 29.690

5.  Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival.

Authors:  Ewa A Jankowska; Bartosz Biel; Jacek Majda; Alicja Szklarska; Monika Lopuszanska; Marek Medras; Stefan D Anker; Waldemar Banasiak; Philip A Poole-Wilson; Piotr Ponikowski
Journal:  Circulation       Date:  2006-10-09       Impact factor: 29.690

6.  Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men.

Authors:  S J Winters; A Brufsky; J Weissfeld; D L Trump; M A Dyky; V Hadeed
Journal:  Metabolism       Date:  2001-10       Impact factor: 8.694

7.  Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit.

Authors:  Molly M Shores; Victoria M Moceri; David A Gruenewald; Kayla I Brodkin; Alvin M Matsumoto; Daniel R Kivlahan
Journal:  J Am Geriatr Soc       Date:  2004-12       Impact factor: 5.562

8.  Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study.

Authors:  Marcello Maggio; Fulvio Lauretani; Gian Paolo Ceda; Stefania Bandinelli; Shari M Ling; E Jeffrey Metter; Andrea Artoni; Laura Carassale; Anna Cazzato; Graziano Ceresini; Jack M Guralnik; Shehzad Basaria; Giorgio Valenti; Luigi Ferrucci
Journal:  Arch Intern Med       Date:  2007-11-12

9.  Inner-city older blacks have high levels of functional disability.

Authors:  D K Miller; M E Carter; J P Miller; J E Fornoff; J A Bentley; S D Boyd; J H Rogers; M N Cox; J E Morley; L Y Lui; R M Coe
Journal:  J Am Geriatr Soc       Date:  1996-10       Impact factor: 5.562

10.  Predictors of serum testosterone and DHEAS in African-American men.

Authors:  Matthew T Haren; William A Banks; H M Perry Iii; Ping Patrick; Theodore K Malmstrom; Douglas K Miller; John E Morley
Journal:  Int J Androl       Date:  2008-02
View more
  3 in total

Review 1.  Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.

Authors:  C Cattabiani; S Basaria; G P Ceda; M Luci; A Vignali; F Lauretani; G Valenti; R Volpi; M Maggio
Journal:  J Endocrinol Invest       Date:  2011-11-08       Impact factor: 4.256

2.  Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome.

Authors:  P Iglesias; F Prado; M C Macías; M T Guerrero; A Muñoz; E Ridruejo; P Tajada; C García-Arévalo; J J Díez
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

3.  Endocrine system dysfunction and chronic heart failure: a clinical perspective.

Authors:  Giuseppe Lisco; Vito Angelo Giagulli; Michele Iovino; Roberta Zupo; Edoardo Guastamacchia; Giovanni De Pergola; Massimo Iacoviello; Vincenzo Triggiani
Journal:  Endocrine       Date:  2021-10-28       Impact factor: 3.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.